Alliance Management Expertise, Partnering Frameworks and Tools, Collaborative Leadership

How to Tame an Octopus: Managing the Proliferation of Clinical Collaborations
1. Partnering Guide / October 15th, 2018
In 2016, former US President Jimmy Carter announced that he no longer required treatment for his metastatic melanoma that had spread to his brain and liver. After six months of being treated with the immunotherapy pembrolizumab (trade name KEYTRUDA), together with surgery and radiation therapy, doctors had seen no sign of his disease for three months. This was a remarkable development—before pembrolizumab was approved in 2011, President Carter’s cancer likely would have been fatal.

Known as a “checkpoint inhibitor” pembrolizumab and other drugs in its class work—in simplest terms—by turbocharging the body’s immune system so that it can fight cancer. Its success, and the success of other similar drugs, such as avelumab (trade name BAVENCIO), and nivolumab (trade name OPDIVO), have unleashed a tsunami of clinical collaborations to identify how using these drugs in combination might expand and extend their significant patient benefits—and maximize their value to the biopharma companies that are developing them.

D...
Taming the Octopus: Managing the Web of Clinical Collaborations
4. News and Events / July 1st, 2018
Jan Twombly, president of The Rhythm of Business is joined by Judy Baselice, director, alliance management at Pfizer and Ellen Locker, executive director, alliance management Merck & Co. at the 2018 ASAP Biopharma Conference in an interactive discussion about the complex web of agreements, restrictions, and obligations resulting from the explosion of clinical collaborations to create combination therapies....
Success through the Biopharma Channel at the ASAP Biopharma Conference
4. News and Events / September 1st, 2017

biopharma imageThe Rhythm of Business is pleased to once again announce our sponsorship of the ASAP Biopharma Conference, the leading conference for life science partnering professionals. This year, we are sharing some of our learning about driving commercial success with local partners, applying some of the lessons learned in the world of information technology.  

In high-tech, the last mile to the customer includes “channel partners” or “resellers.” This is also the case in biopharma – although it is rarely described as a channel.  Leveraging techniques high-tech companies have successfully utilized, we’ll examine practices biopharma companies are adopting to better align with their partners and drive success by ensuring their partners are successful.

Learn what it takes to make your company stand out and be top of mind when it comes to serving patients through the biopharma channel. Educate and engage key stakeholders in adopting your critical processes such as compliance, pharmacovigilance, supply chain, and quality. Help partners leverage your resources and achieve mutual success.

Learn more about the conference and register. It is an event not to be missed!

The Ubiquity of Partnering and Why Every Company Needs the Ability to Partner Everywhere
1. Partnering Guide / October 13th, 2016
AUTHORS: Jan Twombly and Jeff Shuman


Maybe it is starting to sink in. Just maybe it is starting to be understood. The ways and the depth with which we connect with others, connect our organizations, and share data, knowledge, and experience are driving business, societal, and personal value. This means managing external collaborative relationships well – a.k.a. partnerships and alliances – makes a difference in the outcomes we get!

Here are two recent studies that see the light: 

...
From Followers to Leaders: Alliance Management in Biopharma
2. Thought Leadership / November 22nd, 2012
download pdf
Author: Jan Twombly

For its 2012 study of alliance management in the biopharmaceutical industry, The Rhythm of Business surveyed 47 companies from across the globe and found that, on the whole, resources and staffs devoted to alliance management in biopharma are increasing or holdin...
Top